Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Villanueva, K. Tsugawa, T. Toyama, W. Noh, Joon Jeong, F. Cardoso, V. Sriuranpong, V. Srimuninnimit, M. Ozguroglu, S. Kendall, C. Falkson, M. Cianfrocca, C. Manlius, J. Lin, F. Ringeisen, A. Ridolfi, M. Royce (2017)
Abstract P2-11-08: Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trialCancer Research, 77
Christiane, Druml, Wolzt, Pleiner (2000)
World Medical Association Declaration of HelsinkiInternational Journal of Pharmaceutical Medicine, 14
Villanueva (2017)
Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): results from BOLERO-4 trialCancer Res, 77
T. Miller, B. Hennessy, A. González-Angulo, Emily Fox, G. Mills, Heidi Chen, C. Higham, C. García-echeverría, Y. Shyr, C. Arteaga (2010)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.The Journal of clinical investigation, 120 7
F. Cardoso, A. Costa, E. Senkus, M. Aapro, F. André, C. Barrios, J. Bergh, G. Bhattacharyya, L. Biganzoli, M. Cardoso, L. Carey, D. Corneliussen-James, G. Curigliano, V. Diéras, N. Saghir, A. Eniu, L. Fallowfield, D. Fenech, P. Francis, K. Gelmon, A. Gennari, N. Harbeck, C. Hudis, B. Kaufman, I. Krop, M. Mayer, H. Meijer, S. Mertz, S. Ohno, O. Pagani, E. Papadopoulos, F. Peccatori, F. Pernault-Llorca, M. Piccart, J. Pierga, H. Rugo, L. Shockney, G. Sledge, S. Swain, C. Thomssen, A. Tutt, D. Vorobiof, B. Xu, L. Norton, E. Winer (2016)
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).Annals of oncology : official journal of the European Society for Medical Oncology
J. Beck, G. Hortobagyi, M. Campone, F. Lebrun, I. Deleu, H. Rugo, B. Pistilli, N. Masuda, L. Hart, B. Melichar, S. Dakhil, M. Geberth, M. Nunzi, Daniel Heng, T. Brechenmacher, M. El-Hashimy, S. Douma, F. Ringeisen, M. Piccart (2013)
Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2Breast Cancer Research and Treatment, 143
D. Yardley, S. Noguchi, K. Pritchard, H. Burris, J. Baselga, M. Gnant, G. Hortobagyi, M. Campone, B. Pistilli, M. Piccart, B. Melichar, K. Petráková, F. Arena, F. Erdkamp, W. Harb, W. Feng, A. Cahana, T. Taran, D. Lebwohl, H. Rugo (2013)
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival AnalysisAdvances in Therapy, 30
H. Rugo, R. Rumble, E. Macrae, D. Barton, H. Connolly, M. Dickler, L. Fallowfield, B. Fowble, J. Ingle, M. Jahanzeb, S. Johnston, L. Korde, J. Khatcheressian, R. Mehta, H. Muss, H. Burstein (2016)
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 25
M. Gnant (2012)
Overcoming endocrine resistance in breast cancer: importance of mTOR inhibitionExpert Review of Anticancer Therapy, 12
R. Finn, Miguel Martín, H. Rugo, Stephen Jones, S. Im, K. Gelmon, N. Harbeck, O. Lipatov, J. Walshe, S. Moulder, E. Gauthier, D. Lu, S. Randolph, V. Diéras, D. Slamon (2016)
Palbociclib and Letrozole in Advanced Breast Cancer.The New England journal of medicine, 375 20
Governor, Kody Kinsley, Secretary, Mark Payne (2020)
Health and Human ServicesCongress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses
T. Bachelot, C. Bourgier, C. Cropet, I. Ray-Coquard, J. Ferrero, G. Freyer, S. Abadie-Lacourtoisie, J. Eymard, M. Debled, D. Spaëth, E. Legouffe, D. Allouache, C. Kouri, E. Pujade-Lauraine (2012)
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 22
H. Mouridsen, M. Gershanovich, Yan Sun, R. Pérez-Carrión, C. Boni, A. Monnier, J. Apffelstaedt, Robert Smith, H. Sleeboom, F. Jaenicke, A. Płużańska, M. Dank, D. Becquart, P. Bapsy, E. Salminen, R. Snyder, H. Chaudri-Ross, R. Lang, P. Wyld, A. Bhatnagar (2003)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 11
J. Baselga, M. Campone, M. Piccart, H. Burris, H. Rugo, T. Sahmoud, S. Noguchi, M. Gnant, K. Pritchard, F. Lebrun, J. Beck, Yoshinori Ito, D. Yardley, I. Deleu, Alejandra Perez, T. Bachelot, L. Vittori, Zhi-Xia Xu, P. Mukhopadhyay, D. Lebwohl, G. Hortobagyi (2012)
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.The New England journal of medicine, 366 6
(2013)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.JAMA, 310 20
R. Cook, B. Dickens, M. Fathalla (2003)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.The Journal of the American College of Dentists, 81 3
J. Baselga, V. Semiglazov, P. Dam, A. Manikhas, M. Bellet, J. Mayordomo, M. Campone, E. Kubista, R. Greil, G. Bianchi, J. Steinseifer, B. Molloy, E. Tokaji, H. Gardner, P. Phillips, M. Stumm, H. Lane, J. Dixon, W. Jonat, H. Rugo (2009)
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 16
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, Martine Glabbeke, Allan Oosterom, M. Christian, S. Gwyther (2000)
New guidelines to evaluate the response to treatment in solid tumorsBreast Cancer, 12
A. Boulay, Joëlle Rudloff, Jingjing Ye, S. Zumstein-Mecker, T. O'reilly, D. Evans, Shiuan Chen, H. Lane (2005)
Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast CancerClinical Cancer Research, 11
F. Cardoso, A. Costa, E. Senkus, M. Aapro, F. André, C. Barrios, J. Bergh, G. Bhattacharyya, L. Biganzoli, M. Cardoso, L. Carey, D. Corneliussen-James, G. Curigliano, V. Diéras, N. Saghir, A. Eniu, L. Fallowfield, D. Fenech, P. Francis, K. Gelmon, A. Gennari, N. Harbeck, C. Hudis, B. Kaufman, I. Krop, M. Mayer, H. Meijer, S. Mertz, S. Ohno, O. Pagani, E. Papadopoulos, F. Peccatori, F. Penault-Llorca, M. Piccart, J. Pierga, H. Rugo, L. Shockney, G. Sledge, S. Swain, C. Thomssen, A. Tutt, D. Vorobiof, Bing-he Xu, L. Norton, E. Winer (2017)
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).Breast, 31
(2017)
Guidelines in Oncology
A. Wolff, A. Lazar, I. Bondarenko, A. Garin, S. Brincat, L. Chow, Yan Sun, Z. Nešković‐Konstantinović, R. Guimarães, P. Fumoleau, A. Chan, S. Hachemi, A. Strahs, M. Cincotta, A. Berkenblit, M. Krygowski, Lih Kang, L. Moore, D. Hayes (2013)
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 2
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap, G. Sonke, S. Paluch-Shimon, M. Campone, K. Blackwell, F. André, E. Winer, W. Janni, S. Verma, P. Conte, C. Arteaga, D. Cameron, K. Petráková, L. Hart, C. Villanueva, A. Chan, E. Jakobsen, A. Nusch, O. Burdaeva, E. Grischke, E. Alba, E. Wist, N. Marschner, A. Favret, D. Yardley, T. Bachelot, L. Tseng, S. Blau, F. Xuan, F. Souami, Michelle Miller, C. Germa, S. Hirawat, J. O’Shaughnessy (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.The New England journal of medicine, 375 18
H. Rugo, G. Hortobagyi, J. Yao, M. Pavel, A. Ravaud, D. Franz, F. Ringeisen, J. Gallo, N. Rouyrre, O. Anak, R. Motzer (2016)
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacyAnnals of Oncology, 27
Key PointsQuestionDoes first-line everolimus plus endocrine therapy provide a clinical benefit for patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer? FindingsIn this phase 2, single-arm study, 202 patients treated with everolimus plus letrozole in the first-line setting achieved a median progression-free survival of 22.0 months; median overall survival was not reached. For 50 patients whose cancer progressed and who received continued treatment with everolimus plus exemestane, median progression-free survival was 3.7 months. MeaningThese results suggest a rationale for providing first-line everolimus plus letrozole therapy to patients with estrogen receptor–positive advanced breast cancer.
JAMA Oncology – American Medical Association
Published: Jul 22, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.